Log in
NASDAQ:TYME

Tyme Technologies Stock Forecast, Price & News

$0.95
+0.02 (+2.14 %)
(As of 09/25/2020 12:00 AM ET)
Add
Compare
Today's Range
$0.91
Now: $0.95
$1.00
50-Day Range
$0.93
MA: $1.12
$1.35
52-Week Range
$0.86
Now: $0.95
$2.04
Volume412,578 shs
Average Volume753,057 shs
Market Capitalization$121.03 million
P/E RatioN/A
Dividend YieldN/A
Beta0.84
Tyme Technologies, Inc., a clinical-stage biotechnology company, develops novel cancer therapeutics. It is developing SM-88, a combination therapy based on dysfunctional metyrosine derivatives in Phase II development for metastatic pancreatic cancer and biomarker-recurrent prostate cancer. The company was founded in 2011 and is headquartered in New York, New York.
Read More
Tyme Technologies logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.31 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:TYME
CUSIPN/A
Phone212-461-2315

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$0.15 per share

Profitability

Net Income$-22,000,000.00

Miscellaneous

Employees11
Market Cap$121.03 million
Next Earnings Date11/2/2020 (Estimated)
OptionableOptionable
$0.95
+0.02 (+2.14 %)
(As of 09/25/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive TYME News and Ratings via Email

Sign-up to receive the latest news and ratings for TYME and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Tyme Technologies (NASDAQ:TYME) Frequently Asked Questions

How has Tyme Technologies' stock been impacted by Coronavirus?

Tyme Technologies' stock was trading at $1.05 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, TYME shares have decreased by 9.2% and is now trading at $0.9539.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Tyme Technologies?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tyme Technologies in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Tyme Technologies
.

When is Tyme Technologies' next earnings date?

Tyme Technologies is scheduled to release its next quarterly earnings announcement on Monday, November 2nd 2020.
View our earnings forecast for Tyme Technologies
.

How were Tyme Technologies' earnings last quarter?

Tyme Technologies Inc (NASDAQ:TYME) posted its quarterly earnings data on Wednesday, August, 12th. The company reported ($0.06) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.06).
View Tyme Technologies' earnings history
.

What price target have analysts set for TYME?

2 brokers have issued 1-year price targets for Tyme Technologies' shares. Their forecasts range from $9.50 to $9.50. On average, they expect Tyme Technologies' share price to reach $9.50 in the next year. This suggests a possible upside of 895.9% from the stock's current price.
View analysts' price targets for Tyme Technologies
.

Who are some of Tyme Technologies' key competitors?

What other stocks do shareholders of Tyme Technologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Tyme Technologies investors own include Rigel Pharmaceuticals (RIGL), TherapeuticsMD (TXMD), OpGen (OPGN), Sorrento Therapeutics (SRNE), Allena Pharmaceuticals (ALNA), MEI Pharma (MEIP), SCYNEXIS (SCYX), VBI Vaccines (VBIV), Vaxart (VXRT) and Idera Pharmaceuticals (IDRA).

Who are Tyme Technologies' key executives?

Tyme Technologies' management team includes the following people:
  • Mr. Steven E. Hoffman, Co-Founder, Chairman, CEO & Chief Science Officer (Age 56)
  • Mr. Ben R. Taylor, Pres & CFO (Age 42)
  • Mr. Michael S. Demurjian, Co-Founder, Exec. VP, COO & Director (Age 52)
  • Mr. James Biehl J.D., Chief Legal Officer & Sec. (Age 55)
  • Dr. Giuseppe Del Priore, Chief Medical Officer (Age 57)

What is Tyme Technologies' stock symbol?

Tyme Technologies trades on the NASDAQ under the ticker symbol "TYME."

Who are Tyme Technologies' major shareholders?

Tyme Technologies' stock is owned by a variety of institutional and retail investors. Top institutional investors include Hudson Bay Capital Management LP (1.74%), Russell Investments Group Ltd. (0.55%), Nuveen Asset Management LLC (0.29%), Bank of New York Mellon Corp (0.19%), Charles Schwab Investment Management Inc. (0.13%) and Goldman Sachs Group Inc. (0.08%). Company insiders that own Tyme Technologies stock include Barbara Galaini, David Carberry, Douglas A Michels, James Biehl, Michael Demurjian, Michele Ilene Korfin and Steve Hoffman.
View institutional ownership trends for Tyme Technologies
.

Which institutional investors are selling Tyme Technologies stock?

TYME stock was sold by a variety of institutional investors in the last quarter, including Spark Investment Management LLC, Bank of New York Mellon Corp, and UBS Group AG. Company insiders that have sold Tyme Technologies company stock in the last year include Michael Demurjian, and Steve Hoffman.
View insider buying and selling activity for Tyme Technologies
.

Which institutional investors are buying Tyme Technologies stock?

TYME stock was bought by a variety of institutional investors in the last quarter, including Hudson Bay Capital Management LP, Russell Investments Group Ltd., Nuveen Asset Management LLC, Goldman Sachs Group Inc., Jane Street Group LLC, Lido Advisors LLC, and Charles Schwab Investment Management Inc.. Company insiders that have bought Tyme Technologies stock in the last two years include Barbara Galaini, David Carberry, Douglas A Michels, James Biehl, Michele Ilene Korfin, and Steve Hoffman.
View insider buying and selling activity for Tyme Technologies
.

How do I buy shares of Tyme Technologies?

Shares of TYME can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Tyme Technologies' stock price today?

One share of TYME stock can currently be purchased for approximately $0.95.

How big of a company is Tyme Technologies?

Tyme Technologies has a market capitalization of $121.03 million. The company earns $-22,000,000.00 in net income (profit) each year or ($0.17) on an earnings per share basis. Tyme Technologies employs 11 workers across the globe.

What is Tyme Technologies' official website?

The official website for Tyme Technologies is www.tymeinc.com.

How can I contact Tyme Technologies?

Tyme Technologies' mailing address is 17 STATE STREET 7TH FLOOR, NEW YORK NY, 10004. The company can be reached via phone at 212-461-2315 or via email at [email protected]

This page was last updated on 9/26/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.